Cantor Fitzgerald Estimates TG Therapeutics FY2026 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of TG Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the biopharmaceutical company will post earnings of $1.80 per share for the year. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. During the same quarter in the previous year, the firm posted ($0.07) earnings per share. The company's quarterly revenue was up 90.4% on a year-over-year basis.

Other analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Price Performance

TGTX traded down $1.36 on Tuesday, hitting $36.01. 1,671,011 shares of the company's stock were exchanged, compared to its average volume of 2,963,836. TG Therapeutics has a fifty-two week low of $16.21 and a fifty-two week high of $46.48. The stock has a market cap of $5.72 billion, a price-to-earnings ratio of -360.06 and a beta of 1.94. The firm has a 50-day moving average price of $37.24 and a 200-day moving average price of $34.81. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TGTX. Clearbridge Investments LLC purchased a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $55,237,000. Wellington Management Group LLP increased its position in shares of TG Therapeutics by 1,809.9% during the first quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company's stock valued at $47,830,000 after acquiring an additional 1,149,526 shares during the last quarter. Driehaus Capital Management LLC acquired a new stake in shares of TG Therapeutics during the first quarter valued at about $30,545,000. Nuveen LLC purchased a new stake in shares of TG Therapeutics in the 1st quarter valued at approximately $29,442,000. Finally, Woodline Partners LP acquired a new position in shares of TG Therapeutics in the 1st quarter worth approximately $21,021,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.